Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review

被引：3

作者：

Niraula, Saroj ^{[1
,2
]}

机构：

[1] Univ Manitoba, Sect Haematol Oncol, Dept Internal Med, Winnipeg, MB, Canada

[2] CancerCare Manitoba, Winnipeg, MB, Canada

来源：

CANCER | 2019年 / 125卷 / 18期

关键词：

cancer; drug approval; drug regulation; pan-Canadian Oncology Drug Review (pCODR); universal health; CONFLICTS-OF-INTEREST; SOCIETY; BENEFIT;

D O I：

10.1002/cncr.32209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A universal health care system has been a source of both identity and pride for Canadians for the last 6 decades. Currently, Canada actively negotiates the prices of cancer drugs but is not immune to their overwhelming financial toxicities. Prices of cancer drugs are set to ensure maximal profit based on what the market will bear rather than by the value they offer or solely because of the cost of research and development, as often is claimed by the manufacturers. The pan-Canadian Oncology Drug Review (pCODR) is mandated to provide funding recommendations to Canada's provinces and territories. For the most part, the pCODR has been crucial in assessing the cost-effectiveness and feasibility of new drugs in the Canadian context but it could assist more in safeguarding payers against extreme drug costs. Herein, the author suggests a few strategies by which national efforts such as the pCODR and its partners can help Canada to become a leader in facilitating value-based sustainable cancer care.

引用

页码：3100 / 3103

页数：4

共 50 条

[1] Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Rocchi, Angela
Chabot, Isabelle
Glennie, Judith
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 287 - 298
[2] New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations
Niraula, Saroj
Nugent, Zoann
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12): : 1460 - 1466
[3] Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review
Raymakers, Adam J. N.
Regier, Dean A.
Peacock, Stuart J.
[J]. CANCER, 2020, 126 (01) : 148 - 155
[4] CANCER DRUG RECOMMENDATIONS WITHOUT STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW
Whitney, S.
Grima, A.
Samjoo, I
Grima, D.
[J]. VALUE IN HEALTH, 2018, 21 : S47 - S47
[5] Inclusion of health-related quality-of-life data in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers, Adam J. N.
Peacock, Stuart
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
[6] Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations
Trudeau, M.
Hoskins, P.
Reiman, T.
Chambers, A.
Mai, H.
Wheatley-Price, P.
[J]. CURRENT ONCOLOGY, 2017, 24 (02) : 71 - 74
[7] Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding
Srikanthan, A.
Mai, H.
Penner, N.
Amir, E.
Laupacis, A.
Sabharwal, M.
Chan, K. K. W.
[J]. CURRENT ONCOLOGY, 2017, 24 (05) : 295 - 301
[8] POSITIVE CANCER DRUG RECOMMENDATIONS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW ARE NOT WITHOUT CONDITIONS PLACED ON COST-EFFECTIVENESS
Grima, A.
Whitney, S.
Samjoo, I
Grima, D.
[J]. VALUE IN HEALTH, 2018, 21 : S47 - S47
[9] Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review
Hoch, J. S.
Sabharwal, M.
[J]. CURRENT ONCOLOGY, 2013, 20 (02) : 121 - 124
[10] Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada.
Trudeau, Maureen E.
Chambers, Alexandra
Christiansen, Kendra
Mai, Helen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)

← 1 2 3 4 5 →